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Abstract
Purpose Metformin is a commonly used medication for
type II diabetes mellitus. Epidemiologic studies have sug-
gested a decreased relative risk of cancer with metformin
use, and preclinical studies of prostate cancer (PCa) have
shown antitumor activity with metformin. In this study, we
explore the relationship between metformin use and PCa
risk in a population-based case–control study.
Methods Cases were men aged 35–74 years diagnosed
with PCa between 2002 and 2005 in King County, Wash-
ington. Controls were frequency matched by age and
identiﬁed by random digit dialing. Use of metformin was
determined from in-person questionnaires regarding med-
ical and prescription history. The relationship of metformin
use with PCa risk was evaluated using logistic regression.
Results A total of 1,001 cases of PCa and 942 controls
were available for analysis. In Caucasian men, metformin
use was more common in controls than in cases (4.7 vs.
2.8%, p = 0.04), resulting in a 44% risk reduction for PCa
(adjusted OR = 0.56; 95% CI 0.32–1.00). No association
was seen in African-American men.
Conclusion Metformin use was associated with a bor-
derline signiﬁcant decrease in the relative risk of PCa in
Caucasians. Further study into this relationship is needed to
conﬁrm the association and determine the underlying
pathways involved.
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Introduction
Prostate cancer (PCa) is the most common noncutaneous
cancer diagnosed in men, with a 1 in 6 lifetime risk of
developing clinically diagnosed PCa [1]. Type II diabetes
mellitus (DM) is also a common disease, and some studies
have shown a link between PCa and DM [2, 3]. Metformin is
a frequently used medication for patients with DM that has
received increased attention because of a study from phar-
macy and disease databases showing decreased cancer inci-
dence in individuals taking metformin [4]. A second study
reported decreased cancer mortality in diabetic patients tak-
ingmetformincomparedtothosetakingsulfonylureas/insulin
[5]. Several potential mechanisms for this antineoplastic
action of metformin have been suggested, including AMP-
kinasepathway(AMPK)activation[6,7],p-53activation[8],
downregulation of cyclin D1 [7, 9] and suppression of HER2
oncoprotein expression [6]. These ﬁndings are consistent
with animal and in vitro studies demonstrating decreased
growth of a number of different malignant cell types treated
with metformin [6–14], including PCa cell lines [9, 13]. In
this study, using a population-based case–control study of
PCa, we explore the relationship between metformin use and
PCa risk.
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Study participants
The study population consists of participants in a popula-
tion-based case–control study of PCa. Details of the study
participants and data collection have previously been
described [15]. Brieﬂy, cases were Caucasian and African-
American residents of King County, Washington with
histologically conﬁrmed PCa ascertained from the Seattle–
Puget Sound SEER cancer registry and diagnosed between
1 January 2002, and 31 December 2005. Of those eligible
men identiﬁed, 75% (n = 1,001) agreed to participate.
Male residents of King County, Washington with no his-
tory of PCa were identiﬁed as a comparison group using
random digit telephone dialing. Controls were frequency
matched to cases by 5-year age groups and recruited evenly
throughout the ascertainment period for cases. During the
ﬁrst step of random digit dialing, complete household
census information was obtained for 81% of the 24,106
residential telephone numbers contacted. Of eligible men
who were identiﬁed and met the study eligibility criteria,
63% (n = 942) completed the study interview.
Data collection
Subjects completed in-person interviews conducted by
trained interviewers who collected information about
demographic and lifestyle factors, medical, medication use
and family history, and PSA and DRE screening in the
previous 5 years. Participants were asked whether prior to
reference date (date of diagnosis for cases and a randomly
preassigned date for controls that approximated the distri-
bution of diagnosis dates of cases) a doctor ever told them
they had had diabetes; and if so, when they were ﬁrst
diagnosed and what prescription medications they had
used. Up to six different medications could be listed. For
this study, the following drug names for metformin were
reported: metformin, Fortamet, Glucophage, Glucophage
XR, Glumetza, Riomet and Metaglip. The other classes of
diabetic medications were also collected: sulfonyureas
(Amaryl, Glucotrol, Diabeta, Diabinese, Glipizide,
Metaglip), thiazolidinediones (Actos, Avandia, Rezulin,
Rosiglitazone), Insulin (Insulin, Humulin, Lispro, Glar-
gine) and Meglitinides (Starlix).
Statistical analysis
The relative risk of PCa associated with the different dia-
betic treatments was calculated by logistic regression.
Potential confounders that were included in the multivari-
ate model included age, PSA screening history and family
history of PCa. We also adjusted for body mass index
(BMI), statin medication use and aspirin use as these have
been associated with an alteration in the risk of PCa and are
often observed/taken by diabetic men. Effect modiﬁcation
was also examined and revealed evidence of differing
effects of metformin use on PCa risk by race (interaction
p = 0.03). Results were, therefore, stratiﬁed by race. A
second model was created where the primary predictor of
interest was categorized as follows: no diabetes, diabetes –
not taking metformin, diabetes – taking metformin. This
was performed to further evaluate whether it was diabetes
or metformin use impacting PCa risk. Further, polytomous
regression was used to calculate the risk according to dis-
ease aggressiveness (controls, less aggressive, more
aggressive). Disease aggressiveness was based on a com-
posite variable incorporating Gleason score, stage and
PSA, where more aggressive PCa was deﬁned as Gleason
4 ? 3 or greater; nonlocalized stage or PSA C 20 ng/ml at
time of diagnosis. All statistical analyses were conducted
using Stata software, Version 8 (Stata Inc., College Station,
TX).
Results
Table 1 lists the distribution of selected characteristics of
cases and controls. Table 2 lists the proportions of cases
and controls reporting DM and metformin use. The overall
frequencies of DM (9.7 and 10.7%) and metformin use (4.0
and 4.8%) were similar between cases and controls,
respectively. However, results differed by race. Among
Caucasians, DM (7.8 vs. 10.2%, p = 0.09) and metformin
use (2.8 vs. 4.7%, p = 0.04) were less common in cases
compared to controls, respectively. There was no differ-
ence in the frequency of DM or metformin use between
African-American controls and cases, although very lim-
ited numbers were available for this analysis. Increasing
BMI (p\0.001) was associated with a higher prevalence
of metformin use in both cases and controls in both races
(data not shown).
In Table 3, the prevalence of ever use of diabetic and
other medications are provided for cases and controls.
Metformin was the most common medication taken for
diabetes. Use of aspirin and statins was common in both
groups. In Table 4, the age-adjusted and multivariate ORs
and 95% CIs are reported for PCa risk and diabetic treat-
ment in Caucasians. A 39% reduction in the age-adjusted
relative risk (OR = 0.61; 95% CI 0.37–1.02) was seen in
Caucasian men reporting metformin use, but no association
was observed in African-Americans (OR = 1.62; 95% CI
0.53–5.02, data not shown). In the multivariate model
(adjusting for other diabetes treatments, statin and aspirin
uses, BMI, PSA testing and family history of PCa), there
was a 44% reduction in risk of PCa in Caucasians
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where non-metformin treatments of diabetes were grouped
together, the presence of diabetes without metformin use
was not associated with a decrease in PCa risk in the
multivariate model (OR = 0.95, 95% CI 0.60–1.49),
whereas there was a decreased risk in those with diabetes
taking metformin, with a similar OR compared to that for
metformin in the 1st model (OR = 0.66, 95% CI 0.39–
1.11). More aggressive PCa features were present in 31.5%
(n = 315) of cases and the remainder had less aggressive
PCa (n = 686). In the polytomous model, compared to
controls, we found a reduction in risk of PCa associated
with metformin use for both less aggressive PCa
(OR = 0.63, 95% CI 0.33–1.19) and more aggressive PCa
(OR = 0.43, 95% CI 0.17–1.09). The risk estimates for the
PCa aggressiveness categories were not signiﬁcantly dif-
ferent (p = 0.45).
Discussion
In this population-based case–control study, we observed a
borderline signiﬁcant reduction in the relative risk of PCa
in Caucasian men taking the antidiabetic drug metformin.
These results are consistent with ﬁndings from earlier
epidemiologic studies and with preclinical studies demon-
strating antitumor activity of metformin.
Metformin is an oral anti-hyperglycemic medication
used in the management of type II DM that functions pri-
marily through improved insulin sensitivity and decreased
hepatic gluconeogenesis [16]. It is the most common drug
used for treatment of type II DM and has been available in
the United States since 1995 [17]. Metformin has a number
of additional cellular activities that have potential antineo-
plastic activity including AMP-kinase pathway activation
[6, 7], p-53 activation [8], downregulation of cyclin D1 [7,
9], and suppression of HER2 oncoprotein expression [6].
Recently, a Scottish case–control study found a reduced
risk of overall cancer in diabetic patients taking metformin
[5]. In that study, a diabetic clinical information system
was linked to a prescription database and those with any vs.
no metformin exposure had a 23% lower OR for cancer of
any type (OR = 0.77; 95% CI 0.64–0.92). The strongest
risk reduction was observed in those with the longest
durations of metformin use. An additional population-
based study in Saskatchewan linked a prescription database
with a cancer registry and vital statistics database [4].
Diabetic patients taking metformin or a sulfonylurea were
identiﬁed and followed for cancer-speciﬁc mortality.
Table 1 Selected characteristics of prostate cancer cases and controls
Cases n (%) Controls n (%) p-Value
Total 1001 (100) 942 (100)
Age at reference date (years)
35–54 201 (20.1) 209 (22.2) 0.49
55–64 402 (40.2) 361 (38.3)
65–74 398 (39.8) 372 (39.5)
Race
Caucasian 843 (84.2) 844 (89.6) \0.001
African-American 158 (15.8) 98 (10.4)
Family history of prostate cancer
No 775 (77.4) 833 (88.4) \0.001
Yes 226 (22.6) 109 (11.6)
PSA screening within the past 5 years
None 220 (22.0) 240 (25.5) \0.001
1–2 PSAs 172 (17.2) 168 (17.8)
C3 PSAs 546 (54.6) 380 (40.3)
Unknown 63 (6.3) 154 (16.4)
BMI
Normal (\25) 287 (28.7) 259 (27.5) 0.26
Overweight (25–29.9) 492 (49.2) 444 (47.1)
Obese (C30) 222 (22.2) 239 (25.4)
Income
\$50,000 322 (33.6) 309 (33.7) 0.96
$50,000? 637 (66.4) 608 (66.3)
Education
High school only 196 (19.6) 181 (19.2) 0.76
Some college/vocational 241 (24.1) 210 (22.3)
Bachelors degree 262 (26.2) 261 (27.7)
Graduate degree 301 (30.7) 289 (30.7)
Table 2 Distribution of diabetes mellitus and metformin use in cases and controls, by race
All men Caucasians African-Americans
Cases Controls p-Value Cases Controls p-Value Cases Controls p-Value
Diabetes mellitus
No 904 (90.3) 841 (89.3) 0.45 777 (92.2) 758 (89.8) 0.09 127 (80.4) 83 (84.7) 0.38
Yes 97 (9.7) 101 (10.7) 66 (7.8) 86 (10.2) 31 (19.6) 15 (15.3)
Metformin use
No 962 (96.1) 897 (95.2) 0.34 819 (97.2) 804 (95.3) 0.04 143 (90.5) 93 (94.9) 0.20
Yes 40 (4.0) 45 (4.8) 24 (2.8) 40 (4.7) 15 (9.5) 5 (5.1)
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cancer-speciﬁc mortality compared to those taking met-
formin (hazard ratio = 1.3; 95% CI 1.1–1.6). Few studies
have looked speciﬁcally at PCa risk and diabetes treatment.
In a large Finnish population-based registry study, a
decrease in PCa risk was observed for the use of any
antidiabetic drug [18]. This study found that duration of
treatment was inversely related to PCa risk, suggesting that
it is diabetes rather than any speciﬁc medication that
decreases the risk of PCa. However, the investigators were
unable to adjust for BMI, family history of PCa or PSA
screening history. Further, the Finnish population is 98%
Caucasian, so the differences we observed in race cannot
be compared. A multi-ethnic study found an association
between PCa and DM in European-Americans (RR =
0.65, 95% CI 0.50–0.84, p = 0.001) but not in African-
Americans (RR = 0.89, 95% CI 0.77–1.03, p = 0.13) [3].
This was especially true in those with higher Gleason
scores [7 [European-Americans (RR = 0.68, 95% CI
0.43–1.07, p = 0.09) and African-Americans RR = 0.98,
95% CI 0.71–1.29, p = 0.76)]. These results are consistent
with our ﬁndings of effect modiﬁcation of metformin use
by race. Why diabetes and/or treatment effects on PCa risk
would differ by race is unknown. African-American men
often have a delay in diagnosis of DM and worse glycemic
control [19], which may partially explain these ﬁndings.
These differences may also relate to underlying genetic or
environmental exposures and deserve further investigation.
There are several reasons to suspect that metformin may
have speciﬁc anticarcinogenic properties, as it has shown
inhibitory effects in preclinical models of a number of
different tumor types, including prostate [9, 13], breast
[6, 10, 12], pancreatic [11], lung [14] and colon cancers
[8, 13]. In fact, metformin has recently been associated
with increased complete response rates in women with
breast cancer receiving neoadjuvant chemotherapy [20]
and work is underway for Phase III trials of metformin in
early stage breast cancer [21]. PCa risk has been associated
with hyperinsulinemia [22, 23] and unlike sulfonylureas
and exogenous insulin, metformin does not increase insulin
levels [16], which may be one mechanism whereby met-
formin exhibits antitumor activity. Additionally, in PCa
cell lines (LnCaP, PC-3, DU145), metformin has been
shown to inhibit cyclin D1 expression, blocking the cell
cycle in G0/G1 [9]. Metformin has also been shown to
activate AMP-activated protein kinase (AMPK) in PC-3
cell lines [13]. AMPK is activated in response to cellular
stress leading to an increased AMP/ATP ratio [24]. AMPK
has gained attention for its downstream effects of reduced
cellular proliferation and protein synthesis [25] along with
mTOR inhibition [6, 10]. The precise pathway(s) that may
be involved with metformin and its potential antitumor
activity has not been deﬁned and may involve more than
Table 3 Even use of diabetic and other medications by prostate
cancer cases and controls
Cases n (%) Controls n (%)
Diabetes medication usage
Metformin 40 (4.0) 45 (4.8)
Insulin 24 (2.4) 29 (3.1)
Sulfonylureas 14 (1.4) 11 (1.5)
Thiazolidinediones 17 (1.7) 14 (1.5)
Meglitinides 1 (0.1) 1 (0.1)
Other medication usage
Aspirin 484 (48.4) 486 (51.6)
Statins 289 (28.9) 265 (28.1)
Table 4 Age-adjusted and multivariate risk of prostate cancer among Caucasians by diabetes treatment
Age-adjusted model Multivariate model
a
OR 95% CI OR 95% CI
Model 1
Diabetes treatment
Metformin 0.61 0.37–1.02 0.56 0.32–1.00
Insulin 0.76 0.39–1.47 0.95 0.47–1.92
Sulfonylureas 1.28 0.58–2.84 1.79 0.74–4.33
Thiazolidinediones 1.08 0.52–2.25 1.34 0.58–3.13
Diet and exercise only 0.92 0.51–1.65 0.97 0.53–1.78
Model 2
No diabetes 1.00 Referent 1.00 Referent
Diabetes, not taking metformin 0.87 0.56–1.34 0.95 0.60–1.49
Diabetes, taking metformin 0.61 0.37–1.02 0.66 0.39–1.11
a Adjusted for age, other diabetic treatments, aspirin and NSAID usage, bmi, psa tests in preceding 5 years and family history of prostate cancer
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of the speciﬁc pathways that may be involved, our results
draw attention speciﬁcally to PCa risk based on exposure to
metformin and support ongoing efforts to explore the link
between metformin exposure and PCa.
There are limitations of our study. We cannot assess
duration of use of metformin, nor can we distinguish type I
from type II DM. However, early onset type I is rare, and
only three participants (1 case; 2 controls) reported being
diagnosed with DM prior to age 18; exclusion of these men
did not change our results. Overall, 10.7% of our popula-
tion-based controls reported DM, which is similar to the
11% prevalence in the general US population of men over
the age of 20 years [26]. We also rely on participant-
reported use of medications rather than pharmacy records.
In a separate analysis of a subset of this study population
that was designed to validate use of statin medications,
there was 87% agreement between self-reported use and
computerized pharmacy records [15]. There are data
showing a reduced risk of PCa in diabetic men [2, 3], such
that our ﬁndings of a reduced risk in men taking metformin
may be due to an independent aspect of diabetes. Further,
DM may be associated with lower PSA levels [27], which
could introduce detection bias. Additionally, our ﬁnding
may be due to chance and should be replicated in a larger
study. Despite these limitations, these ﬁndings are in sup-
port of the growing evidence from preclinical and epide-
miological data supporting the potential antitumor activity
of metformin. These results indicate that additional studies
are warranted to evaluate the potential metformin-PCa
association.
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